More
mo:re secures 2.3 million euros in seed funding for the future of animal-free drug development
Hamburg, 26 March 2025
mo:re, a life science start-up from Hamburg University of Technology (TUHH), has received seed funding of 2.3 million euros to accelerate the commercialisation of its innovative laboratory platform. The investment was led by High-Tech Gründerfonds (HTGF), with participation from Innovationsstarter Fonds Hamburg (IFH) and international investors such as Gilson Inc, NEDGEX, Nidobirds Ventures and private investors R&R Medical and Martin Blüggel.
The platform developed by mo:re automates the planning, cultivation and analysis of complex 3D cell culture models, setting new standards for animal-free drug development. The aim is to establish organoids as a standard laboratory technique and offer researchers a reproducible, scalable and standardised environment. The start-up is thus responding to current developments such as the FDA's new guidelines, which pave the way for the replacement of animal testing with relevant organoid models.
‘With this funding, we want to expand our market presence and further develop our platform to realise the full potential of animal-free drug research,’ explains Lukas Gaats, CEO of mo:re.
The mo:re platform combines automation and software to optimise the entire cell culture workflow - from sample preparation to analysis. This ensures higher reproducibility and quality while speeding up the research process.
‘The team is well on the way to providing researchers worldwide with an easily accessible, standardised method for performing 3D cell cultures,’ emphasises Dr Christian Kannemeier, Senior Investment Manager at HTGF.
Through the close connection with the TUHH and the support of renowned investors, mo:re wants to play a decisive role in shaping the future of drug research without animal testing.
Further information can be found at www.more.science.
TU Hamburg
Social Media
